Octagam 50 mg/ml infusionsvæske, opløsning เดนมาร์ก - เดนมาร์ก - Lægemiddelstyrelsen (Danish Medicines Agency)

octagam 50 mg/ml infusionsvæske, opløsning

octapharma ab - normalt immunglobulin, humant - infusionsvæske, opløsning - 50 mg/ml

Octagam 100 mg/ml infusionsvæske, opløsning เดนมาร์ก - เดนมาร์ก - Lægemiddelstyrelsen (Danish Medicines Agency)

octagam 100 mg/ml infusionsvæske, opløsning

octapharma ab - normalt immunglobulin, humant - infusionsvæske, opløsning - 100 mg/ml

Subcuvia 160 mg/ml injektionsvæske, opløsning เดนมาร์ก - เดนมาร์ก - Lægemiddelstyrelsen (Danish Medicines Agency)

subcuvia 160 mg/ml injektionsvæske, opløsning

baxalta innovations gmbh - normalt immunglobulin, humant - injektionsvæske, opløsning - 160 mg/ml

Xembify 200 mg/ml injektionsvæske, opløsning เดนมาร์ก - เดนมาร์ก - Lægemiddelstyrelsen (Danish Medicines Agency)

xembify 200 mg/ml injektionsvæske, opløsning

instituto grifols s.a. - normalt immunoglobulin til intravenøs brug, humant - injektionsvæske, opløsning - 200 mg/ml

Imbruvica สหภาพยุโรป - เดนมาร์ก - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Nanogam 50 mg/ml infusionsvæske, opløsning เดนมาร์ก - เดนมาร์ก - Lægemiddelstyrelsen (Danish Medicines Agency)

nanogam 50 mg/ml infusionsvæske, opløsning

prothya biosolutions netherlands b.v. - normalt immunglobulin, humant - infusionsvæske, opløsning - 50 mg/ml

Doptelet สหภาพยุโรป - เดนมาร์ก - EMA (European Medicines Agency)

doptelet

swedish orphan biovitrum ab (publ) - avatrombopag maleate - trombocytopeni - antihemorrhagics - doptelet er indiceret til behandling af svær trombocytopeni hos voksne patienter med kronisk leversygdom, der er planlagt til at blive en invasiv procedure. doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (itp) in adult patients who are refractory to other treatments (e. kortikosteroider, immunglobuliner).

Rhophylac 200 mikrogram injektionsvæske, opløsning i fyldt injektionssprøjte เดนมาร์ก - เดนมาร์ก - Lægemiddelstyrelsen (Danish Medicines Agency)

rhophylac 200 mikrogram injektionsvæske, opløsning i fyldt injektionssprøjte

csl behring gmbh - anti-d immunglobulin, humant - injektionsvæske, opløsning i fyldt injektionssprøjte - 200 mikrogram

Rhophylac 300 mikrogram injektionsvæske, opløsning i fyldt injektionssprøjte เดนมาร์ก - เดนมาร์ก - Lægemiddelstyrelsen (Danish Medicines Agency)

rhophylac 300 mikrogram injektionsvæske, opløsning i fyldt injektionssprøjte

csl behring gmbh - anti-d immunglobulin, humant - injektionsvæske, opløsning i fyldt injektionssprøjte - 300 mikrogram

Uman Big 180 IE/ml injektionsvæske, opløsning เดนมาร์ก - เดนมาร์ก - Lægemiddelstyrelsen (Danish Medicines Agency)

uman big 180 ie/ml injektionsvæske, opløsning

orifarm a/s - hepatitis b immunglobulin, humant - injektionsvæske, opløsning - 180 ie/ml